recombinant human nectin4 his protein (ACROBiosystems)
ACROBiosystems is a verified supplier 
95
Structured Review
ACROBiosystems
recombinant human nectin4 his protein
Recombinant Human Nectin4 His Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+nectin4+his+protein/Human+Nectin-4+Protein%2C+His+Tag/pm41916034-58-0-4
Average 95 stars, based on 3 article reviews
Recombinant Human Nectin4 His Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+nectin4+his+protein/Human+Nectin-4+Protein%2C+His+Tag/pm41916034-58-0-4
Average 95 stars, based on 3 article reviews
recombinant human nectin4 his protein - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Recombinant:Article Title: Design and preclinical evaluation of lipophilicity-enhanced bicyclic peptide probes targeting Nectin4 Labeled with 68 Ga/ 18 F. Article Snippet: Antibody-drug conjugates (ADCs) targeting Nectin4 have shown substantial clinical efficacy in the treatment of progressive or metastatic urothelial carcinoma (mUC).. Accumulating evidence indicates that therapeutic responsiveness to ADCs is closely associated with the level of Nectin4 expression, which can be noninvasively evaluated using positron emission tomography (PET).. However, our previously developed molecular probe, DN68, has displayed predominant renal excretion, a pharmacokinetic feature that may compromise its ability to reliably visualize primary mUC lesions. Concentration Assay:Article Title: Design and preclinical evaluation of lipophilicity-enhanced bicyclic peptide probes targeting Nectin4 Labeled with 68 Ga/ 18 F. Article Snippet: Antibody-drug conjugates (ADCs) targeting Nectin4 have shown substantial clinical efficacy in the treatment of progressive or metastatic urothelial carcinoma (mUC).. Accumulating evidence indicates that therapeutic responsiveness to ADCs is closely associated with the level of Nectin4 expression, which can be noninvasively evaluated using positron emission tomography (PET).. However, our previously developed molecular probe, DN68, has displayed predominant renal excretion, a pharmacokinetic feature that may compromise its ability to reliably visualize primary mUC lesions. Blocking Assay:Article Title: Design and preclinical evaluation of lipophilicity-enhanced bicyclic peptide probes targeting Nectin4 Labeled with 68 Ga/ 18 F. Article Snippet: Antibody-drug conjugates (ADCs) targeting Nectin4 have shown substantial clinical efficacy in the treatment of progressive or metastatic urothelial carcinoma (mUC).. Accumulating evidence indicates that therapeutic responsiveness to ADCs is closely associated with the level of Nectin4 expression, which can be noninvasively evaluated using positron emission tomography (PET).. However, our previously developed molecular probe, DN68, has displayed predominant renal excretion, a pharmacokinetic feature that may compromise its ability to reliably visualize primary mUC lesions. |